We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Neurocrine Biosciences Launches Parkinson’s Add-On Treatment
Neurocrine Biosciences has finally launched its once-daily Parkinson’s disease add-on treatment Ongentys (opicapone) in the U.S. following months of delay brought on by the COVID-19 pandemic.